Ivosidenib and Azacitidine in <i>IDH1</i> -Mutated Acute Myeloid Leukemia

Montesinos, Pau; Récher, Christian; Vives, Susana; Zarzycka, Ewa; Wang, Jianxiang; Bertani, Giambattista; Heuser, Michael; T. Calado, Rodrigo; C. Schuh, Andre; Yeh, Su‐Peng; R. Daigle, Scott; Hui, Jianan; S. Pandya, Shuchi; A. Gianolio, Diego; de Botton, Stéphane; Döhner, Hartmut

doi:10.1056/nejmoa2117344

Public

Ivosidenib and Azacitidine in IDH1 -Mutated Acute Myeloid Leukemia

Published in New England Journal of Medicine • Apr 20, 2022

Authors:

Pau Montesinos

Christian Récher

Susana Vives

Abstract

BACKGROUND: -mutated acute myeloid leukemia. METHODS: -mutated acute myeloid leukemia who were ineligible for intensive induction chemotherapy to receive oral ivosidenib (500 mg once daily) and subcutaneous or intravenous azacitidine (75 mg per square meter of body-surface area for 7 days in 28-day ...

Subject

Azacitidine

Medicine

Placebo

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!